Approaching Neoadjuvant Therapy in the Management of Early-Stage Breast Cancer

References

• DeSantisCE, MaJ, GaudetMM, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69(6):438–451. doi:10.3322/caac.2158331577379
   PubMed Web of Science ®Google Scholar
• AsselainB, BarlowW, BartlettJ, Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018;19(1):27–39. doi:10.1016/S1470-2045(17)30777-529242041
   PubMed Web of Science ®Google Scholar
• WolmarkN, WangJ, MamounasE, BryantJ, FisherB. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001;2001(30):96–102. doi:10.1093/oxfordjournals.jncimonographs.a003469
   Google Scholar
• SpringLM, FellG, ArfeA, et al. Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis. Clin Cancer Res. 2020;26(12):2838–2848. doi:10.1158/1078-0432.CCR-19-349232046998
   PubMed Web of Science ®Google Scholar
• CortazarP, GeyerCEJr. Pathological complete response in neoadjuvant treatment of breast cancer. Ann Surg Oncol. 2015;22(5):1441–1446. doi:10.1245/s10434-015-4404-825727556
   PubMed Web of Science ®Google Scholar
• CortazarP, ZhangL, UntchM, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [published correction appears in Lancet. 2019 Mar 9;393(10175):986]. Lancet. 2014;384(9938):164–172. doi:10.1016/S0140-6736(13)62422-824529560
   PubMed Web of Science ®Google Scholar
• KuererHM, NewmanLA, SmithTL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999;17(2):460–469. doi:10.1200/JCO.1999.17.2.46010080586
   PubMed Web of Science ®Google Scholar
• GuarneriV, BroglioK, KauSW, et al. Prognostic value of pathological complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol. 2006;24:1037–1044. doi:10.1200/JCO.2005.02.691416505422
   PubMed Web of Science ®Google Scholar
• HowladerN, AltekruseSF, LiCI, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5):dju055. doi:10.1093/jnci/dju05524777111
   PubMedGoogle Scholar
• SpringLM, GuptaA, ReynoldsKL, et al. Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2(11):1477–1486. doi:10.1001/jamaoncol.2016.189727367583
   PubMed Web of Science ®Google Scholar
• EiermannW, PaepkeS, AppfelstaedtJ, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol. 2001;12(11):1527–1532. doi:10.1023/a:101312821345111822750
   PubMed Web of Science ®Google Scholar
• CataliottiL, BuzdarAU, NoguchiS, et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative “Arimidex” Compared to Tamoxifen (PROACT) trial. Cancer. 2006;106(10):2095–2103. doi:10.1002/cncr.2187216598749
   PubMed Web of Science ®Google Scholar
• SmithIE, DowsettM, EbbsSR, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 2005;23(22):5108–5116. doi:10.1200/JCO.2005.04.00515998903
   PubMed Web of Science ®Google Scholar
• EllisMJ, SumanVJ, HoogJ, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. J Clin Oncol. 2011;29(17):2342–2349. doi:10.1200/JCO.2010.31.695021555689
   PubMed Web of Science ®Google Scholar
• CarpenterR, DoughtyJC, CordinerC, et al. Optimum duration of neoadjuvant letrozole to permit breast conserving surgery. Breast Cancer Res Treat. 2014;144(3):569–576. doi:10.1007/s10549-014-2835-824562823
   PubMed Web of Science ®Google Scholar
• Krainick-StrobelUE, LichteneggerW, WallwienerD, et al. Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy. BMC Cancer. 2008;8:62. doi:10.1186/1471-2407-8-6218302747
   PubMed Web of Science ®Google Scholar
• RuszO, VörösA, VargaZ, et al. One-year neoadjuvant endocrine therapy in breast cancer. Pathol Oncol Res. 2015;21(4):977–984. doi:10.1007/s12253-015-9911-125753983
   PubMed Web of Science ®Google Scholar
• FonteinDB, CharehbiliA, NortierJW, et al. Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients--a phase II trial. Eur J Cancer. 2014;50(13):2190–2200. doi:10.1016/j.ejca.2014.05.01024970786
   PubMed Web of Science ®Google Scholar
• EllisMJ, TaoY, LuoJ, et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst. 2008;100(19):1380–1388. doi:10.1093/jnci/djn30918812550
   PubMedGoogle Scholar
• EllisMJ, SumanVJ, HoogJ, et al. Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results from the American College of Surgeons Oncology Group Z1031 trial (alliance). J Clin Oncol. 2017;35(10):1061–1069. doi:10.1200/JCO.2016.69.440628045625
   PubMed Web of Science ®Google Scholar
• SumanVJ, EllisMJ, MaCX. The ALTERNATE trial: assessing a biomarker driven strategy for the treatment of post-menopausal women with ER+/Her2- invasive breast cancer. Chin Clin Oncol. 2015;4(3):34. doi:10.3978/j.issn.2304-3865.2015.09.0126408301
   PubMed Web of Science ®Google Scholar
• HurvitzSA, MartinM, PressMF, et al. Potent cell-cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in neoMONARCH, phase II Neoadjuvant Study in HR+/HER2- breast cancer. Clin Cancer Res. 2020;26(3):566–580. doi:10.1158/1078-0432.CCR-19-142531615937
   PubMed Web of Science ®Google Scholar
• JohnstonS, PuhallaS, WheatleyD, et al. Randomized Phase II Study evaluating palbociclib in addition to letrozole as neoadjuvant therapy in estrogen receptor-positive early breast cancer: PALLET trial. J Clin Oncol. 2019;37(3):178–189. doi:10.1200/JCO.18.0162430523750
   PubMed Web of Science ®Google Scholar
• PratA, SauraC, PascualT, et al. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2020;21(1):33–43. doi:10.1016/S1470-2045(19)30786-731838010
   PubMed Web of Science ®Google Scholar
• SauraC, HlauschekD, OliveiraM, et al. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2019;20(9):1226–1238. doi:10.1016/S1470-2045(19)30334-131402321
   PubMed Web of Science ®Google Scholar
• LoiS, McArthurHL, HarbeckN, et al. A phase III trial of nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+/HER2- primary breast cancer: checkMate 7FL. J Clin Oncol. 2020;38(15_suppl):TPS604–TPS604. doi:10.1200/JCO.2020.38.15_suppl.TPS604
   Google Scholar
• CardosoF, BardiaA, AndreF, et al. KEYNOTE-756: a randomized, double-blind, phase III study of pembrolizumab versus placebo in combination with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk early-stage ER+/HER2– breast cancer [abstract] In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 124–8, 2018; San Antonio, TX. Philadelphia (PA): AACR. Cancer Res 2019; 79(4Suppl):Abstract nr OT3-04-03. doi: 10.1158/1538-7445.SABCS18-OT3-04-03
   Google Scholar
• SlamonDJ, ClarkGM, WongSG, LevinWJ, UllrichA, McGuireWL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177–182. doi:10.1126/science.37981063798106
   PubMed Web of Science ®Google Scholar
• BroglioKR, QuintanaM, FosterM, et al. Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes: a meta-analysis. JAMA Oncol. 2016;2(6):751–760. doi:10.1001/jamaoncol.2015.611326914222
   PubMed Web of Science ®Google Scholar
• RobidouxA, TangG, RastogiP, et al. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol. 2013;14(12):1183–1192. doi:10.1016/S1470-2045(13)70411-X24095300
   PubMed Web of Science ®Google Scholar
• van der VoortA, van RamshorstMS, van WerkhovenED, et al. Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2-positive breast cancer (TRAIN-2): a randomized phase III trial. J Clin Oncol. 2020;38S:ASCO #501.
   Google Scholar
• SchneeweissA, ChiaS, HickishT, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24(9):2278–2284. doi:10.1093/annonc/mdt18223704196
   PubMed Web of Science ®Google Scholar
• GianniL, EiermannW, SemiglazovV, et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort [published correction appears in Lancet Oncol. 2018 Dec;19(12):e667]. Lancet Oncol. 2014;15(6):640–647. doi:10.1016/S1470-2045(14)70080-424657003
   PubMed Web of Science ®Google Scholar
• GianniL, PienkowskiT, ImYH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25–32. doi:10.1016/S1470-2045(11)70336-922153890
   PubMed Web of Science ®Google Scholar
• BriaE, CarbogninL, FurlanettoJ, et al. Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: sensitivity analysis of randomized trials. Cancer Treat Rev. 2014;40(7):847–856. doi:10.1016/j.ctrv.2014.05.00124877987
   PubMed Web of Science ®Google Scholar
• von MinckwitzG, HuangCS, ManoMS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617–628. doi:10.1056/NEJMoa181401730516102
   PubMed Web of Science ®Google Scholar
• SlamonD, EiermannW, RobertN, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273–1283. doi:10.1056/NEJMoa091038321991949
   PubMed Web of Science ®Google Scholar
• von MinckwitzG, ProcterM, de AzambujaE, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer [published correction appears in N Engl J Med. 2017 Aug 17;377(7):702][published correction appears in N Engl J Med. 2018 Oct 18;379(16):1585]. N Engl J Med. 2017;377(2):122–131. doi:10.1056/NEJMoa170364328581356
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Breast cancer (Version 1.2021). Available from:https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf. Accessed 130, 2021.
   Google Scholar
• Gonzalez-AnguloAM, LittonJK, BroglioKR, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol. 2009;27(34):5700–5706. doi:10.1200/JCO.2009.23.202519884543
   PubMed Web of Science ®Google Scholar
• CuriglianoG, VialeG, BagnardiV, et al. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol. 2009;27(34):5693–5699. doi:10.1200/JCO.2009.22.096219884553
   PubMed Web of Science ®Google Scholar
• TheriaultRL, LittonJK, MittendorfEA, et al. Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype. Clin Breast Cancer. 2011;11(5):325–331. doi:10.1016/j.clbc.2011.05.00221764391
   PubMed Web of Science ®Google Scholar
• JoensuuH, IsolaJ, LundinM, et al. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res. 2003;9(3):923–930.12631589
   PubMed Web of Science ®Google Scholar
• HowlanderN, NooneA, KrapchoM, MillerD, BrestA, YuM. SEER Cancer Statistics Review, 1975–2017. Bethesda, MD: National Cancer Institute; 2017.
   Google Scholar
• BiswasT, EfirdJT, PrasadS, JindalC, WalkerPR. The survival benefit of neoadjuvant chemotherapy and pCR among patients with advanced stage triple negative breast cancer. Oncotarget. 2017;8(68):112712–112719. doi:10.18632/oncotarget.2252129348858
   PubMedGoogle Scholar
• von MinckwitzG, UntchM, BlohmerJU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):1796–1804. doi:10.1200/JCO.2011.38.859522508812
   PubMed Web of Science ®Google Scholar
• SpringLM, FellG, ArfeA, et al. Pathological complete response (pCR) after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival, stratified by breast cancer subtypes and adjuvant chemotherapy usage: patient-level meta-analyses of over 27,000 patients. Proceedings from the 2018 San Antonio Breast Cancer Symposium (SABCS); 124–8, 2018; San Antonio, TX.
   Google Scholar
• Vaz-LuisI, OttesenRA, HughesME, et al. Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J Clin Oncol. 2014;32(20):2142–2150. doi:10.1200/JCO.2013.53.160824888816
   PubMed Web of Science ®Google Scholar
• BlumJL, FlynnPJ, YothersG, et al. Anthracyclines in early breast cancer: the ABC trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG oncology). J Clin Oncol. 2017;35(23):2647–2655. doi:10.1200/JCO.2016.71.414728398846
   PubMed Web of Science ®Google Scholar
• SikovWM, BerryDA, PerouCM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015;33(1):13–21. doi:10.1200/JCO.2014.57.057225092775
   PubMed Web of Science ®Google Scholar
• YuanY, LeeJS, YostSE, et al. Phase II trial of neoadjuvant carboplatin and nab-paclitaxel in patients with triple-negative breast cancer [published online ahead of print, 2020 Oct 24]. Oncologist. 2020. doi:10.1002/onco.13574
   Web of Science ®Google Scholar
• LoiblS, O’ShaughnessyJ, UntchM, et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 2018;19(4):497–509. doi:10.1016/S1470-2045(18)30111-629501363
   PubMed Web of Science ®Google Scholar
• HahnenE, LedererB, HaukeJ, et al. Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial. JAMA Oncol. 2017;3(10):1378–1385. doi:10.1001/jamaoncol.2017.100728715532
   PubMed Web of Science ®Google Scholar
• LoiblS, WeberKE, TimmsKM, et al. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto. Ann Oncol. 2018;29(12):2341–2347. doi:10.1093/annonc/mdy46030335131
   PubMed Web of Science ®Google Scholar
• GarufiG, PalazzoA, ParisI, et al. Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors. Expert Opin Pharmacother. 2020;21(6):687–699. doi:10.1080/14656566.2020.172495732052646
   PubMed Web of Science ®Google Scholar
• NandaR, LiuMC, YauC, et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol. 2020;6(5):676–684. doi:10.1001/jamaoncol.2019.665032053137
   PubMed Web of Science ®Google Scholar
• SchmidP, CortesJ, PusztaiL, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810–821. doi:10.1056/NEJMoa191054932101663
   PubMed Web of Science ®Google Scholar
• MittendorfEA, ZhangH, BarriosCH, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020;396(10257):1090–1100. doi:10.1016/S0140-6736(20)31953-X32966830
   PubMed Web of Science ®Google Scholar
• GianniL, HuangCS, EgleD, et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 michelangelo randomized study. Cancer Res. 2019;80S:SABCS #GS3-04.
   Google Scholar
• MasudaN, LeeSJ, OhtaniS, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147–2159. doi:10.1056/NEJMoa161264528564564
   PubMed Web of Science ®Google Scholar
• HanceKW, AndersonWF, DevesaSS, YoungHA, LevinePH. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst. 2005;97(13):966–975. doi:10.1093/jnci/dji17215998949
   PubMed Web of Science ®Google Scholar
• UenoNT, BuzdarAU, SingletarySE, et al. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol. 1997;40(4):321–329. doi:10.1007/s0028000506649225950
   PubMed Web of Science ®Google Scholar
• BaldiniE, GardinG, EvagelistaG, ProchiloT, CollecchiP, LionettoR. Long-term results of combined-modality therapy for inflammatory breast carcinoma. Clin Breast Cancer. 2004;5(5):358–363. doi:10.3816/cbc.2004.n.04215585073
   PubMedGoogle Scholar
• GianniL, EiermannW, SemiglazovV, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010;375(9712):377–384. doi:10.1016/S0140-6736(09)61964-420113825
   PubMed Web of Science ®Google Scholar
• KordeLA, SomerfieldMR, CareyLA, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast Cancer: ASCO guideline [published online ahead of print, 2021 Jan 28]. J Clin Oncol. 2021;JCO2003399. doi:10.1200/JCO.20.03399
   Web of Science ®Google Scholar
• FisherB, BryantJ, WolmarkN, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16(8):2672–2685. doi:10.1200/JCO.1998.16.8.26729704717
   PubMed Web of Science ®Google Scholar
• GianniL, BaselgaJ, EiermannW, et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res. 2005;11(24 Pt 1):8715–8721. doi:10.1158/1078-0432.CCR-05-053916361558
   PubMed Web of Science ®Google Scholar
• GolshanM, CirrincioneCT, SikovWM, et al. Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance). Breast Cancer Res Treat. 2016;160(2):297–304. doi:10.1007/s10549-016-4006-627704226
   PubMed Web of Science ®Google Scholar
• GolshanM, LoiblS, WongSM, et al. Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from the BrighTNess randomized clinical trial. JAMA Surg. 2020;155(3):e195410. doi:10.1001/jamasurg.2019.541031913413
   PubMed Web of Science ®Google Scholar
• MamtaniA, AvB, TaK, et al. How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? Results of a Prospective Study. Ann Surg Oncol. 2016;23(11):3467–3474. doi:10.1245/s10434-016-5246-827160528
   PubMed Web of Science ®Google Scholar
• BougheyJC, SumanVJ, MittendorfEA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455–1461. doi:10.1001/jama.2013.27893224101169
   PubMed Web of Science ®Google Scholar
• BougheyJC, BallmanKV, Le-petrossHT, et al. Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0-T4, N1-N2) who receive neoadjuvant chemotherapy: results from ACOSOG Z1071 (alliance). Ann Surg. 2016;263(4):802–807. doi:10.1097/SLA.000000000000137526649589
   PubMed Web of Science ®Google Scholar
• CaudleAS, YangWT, KrishnamurthyS, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34(10):1072–1078. doi:10.1200/JCO.2015.64.009426811528
   PubMed Web of Science ®Google Scholar
• OlivottoIA, LesperanceML, TruongPT, et al. Intervals longer than 20 weeks from breast-conserving surgery to radiation therapy are associated with inferior outcome for women with early-stage breast cancer who are not receiving chemotherapy [published correction appears in J Clin Oncol. 2009 May 10;27(14):2415]. J Clin Oncol. 2009;27(1):16–23. doi:10.1200/JCO.2008.18.189119018080
   PubMed Web of Science ®Google Scholar
• PhanC, MindrumM, SilvermanC, ParisK, SpanosW. Matched-control retrospective study of the acute and late complications in patients with collagen vascular diseases treated with radiation therapy. Cancer J. 2003;9(6):461–466. doi:10.1097/00130404-200311000-0000514740974
   PubMed Web of Science ®Google Scholar
• ChenAM, ObedianE, HafftyBG. Breast-conserving therapy in the setting of collagen vascular disease. Cancer J. 2001;7(6):480–491.11769860
   PubMed Web of Science ®Google Scholar
• HolmesD, ColfryA, CzernieckiB, et al. Performance and practice guideline for the use of neoadjuvant systemic therapy in the management of breast cancer. Ann Surg Oncol. 2015;22(10):3184–3190. doi:10.1245/s10434-015-4753-326224406
   PubMed Web of Science ®Google Scholar
• BarkerAD, SigmanCC, KelloffGJ, HyltonNM, BerryDA, EssermanLJ. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther. 2009;86(1):97–100. doi:10.1038/clpt.2009.6819440188
   PubMed Web of Science ®Google Scholar